Pomerantz LLP has filed a class action lawsuit against GRAIL, Inc. regarding alleged violations of federal securities laws, adding to previous legal actions targeting the company. The lawsuit concerns whether GRAIL and certain of its officers and/or directors engaged in securities fraud or other unlawful business practices. Investors who purchased or otherwise acquired GRAIL securities between May 13, 2025, and February 19, 2026, are affected by this litigation.

The legal action centers on the NHS-Galleri trial. On February 19, 2026, GRAIL announced that the primary endpoint of a statistically significant reduction in Stage III–IV cancers was not observed. The company attributed this outcome partly to probably needing a longer follow-up time to compare the study arms adequately. Following this announcement, GRAIL's stock price fell more than 50%, damaging investors.

Investors who wish to serve as lead plaintiff must act promptly, as the Court sets a deadline to appoint a representative party for the class. Those who inquire by email are encouraged to include their mailing address, telephone number, and the number of shares purchased. Shareholders may choose counsel of their choice or remain an absent class member. Until certification occurs, investors are not represented by an attorney unless they take action.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as a premier firm in corporate, securities, and antitrust class litigation. The firm was founded by Abraham L. Pomerantz, known as the dean of the class action bar. Interested investors may contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.